John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
OKLAHOMA CITY, July 24, 2017 -- Cytovance hosted an unannounced FDA inspection Tuesday, July 11th 2017. The inspector conducted the inspection over an eight day period and focused on Quality Systems. Overall the inspection was very positive and the inspector acknowledged that the site had already identified and taken action on most of the 4 observations. Specifically, Cytovance had taken action to address the facility improvements. All the facility updates are scheduled to be completed during Cytovance’s end of summer shutdown.
“This was a great stepping stone for our quality systems and facility as we get close to our first PAI which we expect later in the year” stated Cytovance’s Vice President of Quality, Maria Lopez. “I am proud of my team and this inspection reiterates Cytovance’s commitment to become a first in class contract manufacturer of our client’s parenteral drug candidates.”
“Cytovance remains committed to providing the highest quality services and therapeutics to our clients,” said Darren Head, president and CEO of Cytovance Biologics, “I know we will work diligently together to complete these actions in a timely manner.”
About Cytovance Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Media Contact Cheryl Tuck 405-319-8309 [email protected]
